Navigation Links
Proacta Incorporated Announces IND Allowance for PR610
Date:8/29/2012

SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.

The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed resistance to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib. In such cases, no effective treatment is currently available.

The first clinical study will be conducted at sites in the US and New Zealand. Proacta expects to initiate patient enrollment in the coming weeks.

About PR610

PR610 is Proacta's proprietary hypoxia-activated irreversible MKI discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. Reversible MKI's are currently used for the treatment of several types of cancer. However, resistance often develops to reversible MKI's and side effects limit their use at higher doses.

PR610 utilizes an irreversible MKI that is activated in areas of severe hypoxia, a characteristic of most solid tumors. Localized release of the irreversible MKI within tumors leads to higher tumor concentrations and lower concentrations in normal tissues, which should result in improved efficacy and fewer side effects. In addition, irreversible MKI inhibitors are not affected by some of the resistance mechanisms that limit use of reversible MKI inhibitors.

In subsequent studies, Proacta expects to evaluate PR610 in other cancers that are currently treated with first-generation reversible tyrosine kinase inhibitors such as gastric, breast, and pancreatic.

In 2011, Proacta engaged in the collaboration for research, development and commercialization of PR610 in Japan with Yakult Honsha Co., Ltd. whose pharmaceutical business is focused on oncology.

About Proacta Incorporated

Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta has a pipeline of hypoxia-activated prodrugs for the treatment of cancer that are licensed from the University of Auckland in New Zealand. For more information, visit the Proacta web site at www.proacta.com.


'/>"/>
SOURCE Proacta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
2. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
3. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
4. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
5. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
6. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
7. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Tribogenics Announces Dual-Energy X-ray Source for XRF
10. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
11. Cynosure Announces Upcoming Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):